Effect of α-receptor blockers on lower urinary tract symptoms, sexual function and quality of life in young and middle-aged men with benign prostatic hyperplasia

Michel MC: Words of wisdom: Re: a randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. Eur Urol. 69:174–179. 2016. View Article : Google Scholar : PubMed/NCBI

Li H, Yang J, Zhao H, Fossler MJ and Wang C: Effect of tamsulosin on the pharmacokinetics of dutasteride in Chinese male healthy volunteers. Clin Pharmacol Drug Dev. 4:427–433. 2015. View Article : Google Scholar : PubMed/NCBI

Dimitropoulos K and Gravas S: Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia. Ther Adv Urol. 8:19–28. 2016. View Article : Google Scholar : PubMed/NCBI

Kaplan SA: Re: comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. J Urol. 196:503–505. 2016. View Article : Google Scholar : PubMed/NCBI

Nazir J, Heemstra L, van Engen A, Hakimi Z and Ivanescu C: Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia. BMC Urol. 15:41–45. 2015. View Article : Google Scholar : PubMed/NCBI

Traish AM, Haider KS, Doros G and Haider A: Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia. Horm Mol Biol Clin Investig. 23:85–96. 2015.PubMed/NCBI

Udeh EI, Ofoha CG, Adewole DA and Nnabugwu II: A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model. BMC Cancer. 16:4052016. View Article : Google Scholar : PubMed/NCBI

Stojanović N, Ignjatović I, Djenić N and Bogdanović D: Adverse effects of pharmacological therapy of benign prostatic hyperplasia on sexual function in men. Srp Arh Celok Lek. 143:284–289. 2015. View Article : Google Scholar : PubMed/NCBI

Kosilov KV, Loparev SA, Ivanovskaya MA and Kosilova LV: Effectiveness of solifenacin and trospium for managing of severe symptoms of overactive bladder in patients with benign prostatic hyperplasia. Am J Men Health. 10:157–163. 2016. View Article : Google Scholar

Russo A, Capogrosso P, La Croce G, Ventimiglia E, Boeri L, Briganti A, Damiano R, Montorsi F and Salonia A: Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia. Expert Opin Drug Saf. 15:1661–1670. 2016. View Article : Google Scholar : PubMed/NCBI

Krivoborodov GG and Tur EI: Long-term outcomes of the use of α-blockers tamsulosin in men with lower urinary tract symptoms and benign prostatic hyperplasia. Urologiia. 1247–48. (50)2014.(In Russian).

Karami H, Hassanzadeh-Hadad A and Fallah-Karkan M: Comparing monotherapy with tadalafil or tamsulosin and their combination therapy in men with benign prostatic hyperplasia: a randomized clinical trial. Urol J. 13:2920–2926. 2016.PubMed/NCBI

Barkin J, Diles D, Franks B and Berner T: Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence. Can J Urol. 22:7914–7923. 2015.PubMed/NCBI

Fusco F, Palmieri A, Ficarra V, Giannarini G, Novara G, Longo N, Verze P, Creta M and Mirone V: α1-blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol. 69:1091–1101. 2016. View Article : Google Scholar : PubMed/NCBI

Utsunomiya N, Matsumoto K, Tsunemori H, Muguruma K, Kawakita M, Kamiyama Y, Kanamaru S, Ito N, Tsukazaki H, Shirahase T, et al: A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin. Hinyokika Kiyo. 62:341–347. 2016.(In Japanese). PubMed/NCBI

Latil A, Pétrissans MT, Rouquet J, Robert G and de la Taille A: Effects of hexanic extract of serenoa repens (Permixon^® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 75:1857–1867. 2015. View Article : Google Scholar : PubMed/NCBI

Choi JD, Kim JH and Ahn SH: Transitional zone index as a predictor of the efficacy of α-blocker and 5α-reductase inhibitor combination therapy in Korean patients with benign prostatic hyperplasia. Urol Int. 96:406–412. 2016. View Article : Google Scholar : PubMed/NCBI

Takeshita H, Moriyama S, Arai Y, Washino S, Saito K, Chiba K, Horiuchi S and Noro A: Randomized crossover comparison of the short-term efficacy and safety of single half-dose silodosin and tamsulosin hydrochoride in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Low Urin Tract Symptoms. 8:38–43. 2016. View Article : Google Scholar : PubMed/NCBI

Terakado M, Suzuki H, Hashimura K, Tanaka M, Ueda H, Kohno H, Fujimoto T, Saga H, Nakade S, Habashita H, et al: Discovery of ONO-7300243 from a novel class of lysophosphatidic acid receptor 1 antagonists: from hit to lead. ACS Med Chem Lett. 7:913–918. 2016. View Article : Google Scholar : PubMed/NCBI

Seftel AD: Re: finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia. J Urol. 195:1392016. View Article : Google Scholar : PubMed/NCBI